Indraprastha Medical Q2 FY27 Results Due October 29

Indraprastha Medical Corporation Ltd. is scheduled to report its Q2 FY27 results on October 29, 2026, according to the earnings-date information provided. The September-quarter disclosure will follow a stronger June quarter, when the company reported net sales of ₹406.15 crore. Revenue was up 11.26% year-on-year and 11.33% sequentially. The release is relevant because it will show whether the improvement in revenue and operating profit continued through the July to September period.

Q2 FY27 earnings date is listed as October 29

The available earnings calendar identifies October 29, 2026, as the date for Indraprastha Medical's Q2 FY27 results. Other material in the supplied data says a board-meeting intimation had not been filed with the exchanges as of September 16, 2026. That earlier status does not confirm or disprove the later calendar date. Investors should therefore rely on the company’s exchange filing for the final timing and the complete financial statements.

The Q2 FY27 period covers July 1, 2026 to September 30, 2026. Under Indian listing requirements cited in the supplied material, quarterly results must be published within 45 days of the quarter-end. This places November 14, 2026 as the stated outer deadline for the September-quarter results.

June quarter revenue reached ₹406.15 crore

For Q1 FY27, Indraprastha Medical reported standalone net sales of ₹406.15 crore. This compares with ₹365.06 crore in Q1 FY26 and represents year-on-year growth of 11.26%. The company’s June-quarter sales were also above ₹364.81 crore reported in the preceding March 2026 quarter.

The supplied quarterly-results series records sales of ₹381.03 crore in the September 2025 quarter. That figure is the direct year-ago revenue base for the upcoming September 2026 comparison. No verified revenue estimate for Q2 FY27 is included in the supplied information.

Operating profit improved in the first quarter

Operating profit for the June 2026 quarter was ₹79.81 crore, compared with ₹73.15 crore a year earlier. Total expenditure stood at ₹326.34 crore, against ₹291.91 crore in Q1 FY26. The difference between net sales and total expenditure supported the higher operating profit reported for the quarter.

The quarterly data also shows operating profit of ₹60.51 crore in March 2026. The June-quarter operating profit was therefore higher than the immediately preceding quarter. Other income was ₹8.42 crore in Q1 FY27, while interest cost was ₹1.65 crore.

Net profit was reported at about ₹56 crore

The data states Q1 FY27 net profit at ₹56 crore, compared with ₹51 crore in Q1 FY26, implying growth of 9.80%. A separate summary lists net profit at ₹55 crore, with 8.53% year-on-year growth and 33.93% quarter-on-quarter growth. Another earnings summary cites net income of ₹55.85 crore.

These small differences appear to arise from rounding and differing data presentations. The company’s reported filing and results release remain the appropriate reference for exact figures. For the September 2025 quarter, the supplied information gives net profit of ₹49 crore, which forms the stated Q2 FY26 comparison base.

Quarterly sales trend has moved upward

Indraprastha Medical’s quarterly sales rose from ₹307 crore in June 2023 to ₹406 crore in June 2026 in the historical series provided. The path was not uniform. Sales moved from ₹365 crore in June 2025 to ₹381 crore in September 2025, before declining to ₹371 crore in December 2025 and ₹365 crore in March 2026.

The June 2026 result marked a recovery from those two preceding quarters. Operating profit followed a similar recent pattern, rising to ₹79.81 crore in June 2026 from ₹60.51 crore in March 2026. The Q2 result will provide the next confirmed data point on revenue and operating performance.

Key reported quarterly figures

All absolute figures have been expressed in crore rupees. The supplied material also refers to first-quarter revenue of ₹4.15 billion and net income of ₹558.5 million, equivalent to approximately ₹415 crore and ₹55.85 crore respectively. Those figures differ slightly from the standalone quarterly table.

What investors can compare in the Q2 release

The September-quarter filing will allow a comparison with revenue of ₹381.03 crore and net profit of ₹49 crore in Q2 FY26. It will also be assessed against Q1 FY27, when sales were ₹406.15 crore and operating profit was ₹79.81 crore. The company has not provided a verified consensus estimate in the information supplied.

The material specifically notes that no numerical revenue or profit forecast should be assumed for the coming quarter. As a result, the reported numbers, margins, expenses, other income and any exceptional items will be central to evaluating the quarter once results are released.

Industry growth comparison is part of the backdrop

An earnings summary in the supplied data states that Indraprastha Medical’s revenue is forecast to grow at an average annual rate of 5.9% over the next two years. The same source places the India healthcare industry growth forecast at 18% over that period. These are forecast figures, rather than reported company results.

The comparison provides context for the upcoming financial disclosures but does not establish the company’s Q2 outcome. The October 29 release, if confirmed through the company’s filing, will provide the next reported update on its financial performance.

Conclusion

Indraprastha Medical enters its scheduled Q2 FY27 results date after reporting ₹406.15 crore in Q1 revenue, ₹79.81 crore in operating profit and about ₹56 crore in net profit. The September-quarter results will be compared with the year-ago base of ₹381.03 crore in revenue and ₹49 crore in net profit. The company’s exchange announcement and quarterly filing will provide the final schedule and detailed figures.